CN117919365A - Traditional Chinese medicine composition for preventing and treating alcoholic liver injury as well as preparation method and application thereof - Google Patents
Traditional Chinese medicine composition for preventing and treating alcoholic liver injury as well as preparation method and application thereof Download PDFInfo
- Publication number
- CN117919365A CN117919365A CN202311710863.3A CN202311710863A CN117919365A CN 117919365 A CN117919365 A CN 117919365A CN 202311710863 A CN202311710863 A CN 202311710863A CN 117919365 A CN117919365 A CN 117919365A
- Authority
- CN
- China
- Prior art keywords
- parts
- liver
- traditional chinese
- alcoholic liver
- liver injury
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 58
- 239000000203 mixture Substances 0.000 title claims abstract description 49
- 206010067125 Liver injury Diseases 0.000 title claims abstract description 42
- 231100000753 hepatic injury Toxicity 0.000 title claims abstract description 42
- 230000001476 alcoholic effect Effects 0.000 title claims abstract description 41
- 238000002360 preparation method Methods 0.000 title abstract description 16
- 210000004185 liver Anatomy 0.000 claims abstract description 74
- 239000000463 material Substances 0.000 claims abstract description 34
- 238000002156 mixing Methods 0.000 claims abstract description 34
- 210000002784 stomach Anatomy 0.000 claims abstract description 33
- 244000037364 Cinnamomum aromaticum Species 0.000 claims abstract description 27
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 claims abstract description 27
- 210000000952 spleen Anatomy 0.000 claims abstract description 24
- 235000006886 Zingiber officinale Nutrition 0.000 claims abstract description 23
- 235000008397 ginger Nutrition 0.000 claims abstract description 23
- 241000132012 Atractylodes Species 0.000 claims abstract description 22
- 244000303040 Glycyrrhiza glabra Species 0.000 claims abstract description 22
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 22
- 241000237502 Ostreidae Species 0.000 claims abstract description 22
- 240000006079 Schisandra chinensis Species 0.000 claims abstract description 22
- 235000020636 oyster Nutrition 0.000 claims abstract description 22
- 235000008599 Poria cocos Nutrition 0.000 claims abstract description 20
- 244000197580 Poria cocos Species 0.000 claims abstract description 20
- 235000008422 Schisandra chinensis Nutrition 0.000 claims abstract description 19
- 235000009051 Ambrosia paniculata var. peruviana Nutrition 0.000 claims abstract description 18
- 235000003097 Artemisia absinthium Nutrition 0.000 claims abstract description 18
- 240000001851 Artemisia dracunculus Species 0.000 claims abstract description 18
- 235000017731 Artemisia dracunculus ssp. dracunculus Nutrition 0.000 claims abstract description 18
- 235000003261 Artemisia vulgaris Nutrition 0.000 claims abstract description 18
- 239000001138 artemisia absinthium Substances 0.000 claims abstract description 18
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims abstract description 18
- 241000220436 Abrus Species 0.000 claims abstract description 8
- 241000049624 Alisma plantago-aquatica subsp. orientale Species 0.000 claims abstract description 4
- 241000212322 Levisticum officinale Species 0.000 claims abstract description 4
- 244000046146 Pueraria lobata Species 0.000 claims abstract description 4
- 235000010575 Pueraria lobata Nutrition 0.000 claims abstract description 4
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims abstract description 4
- 239000001645 levisticum officinale Substances 0.000 claims abstract description 4
- 235000011477 liquorice Nutrition 0.000 claims abstract description 4
- 244000273928 Zingiber officinale Species 0.000 claims abstract 4
- 239000006228 supernatant Substances 0.000 claims description 34
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 24
- 239000002994 raw material Substances 0.000 claims description 23
- 241000382455 Angelica sinensis Species 0.000 claims description 22
- 208000002193 Pain Diseases 0.000 claims description 21
- 230000036407 pain Effects 0.000 claims description 21
- 241000628997 Flos Species 0.000 claims description 20
- 241000112528 Ligusticum striatum Species 0.000 claims description 19
- 235000017443 Hedysarum boreale Nutrition 0.000 claims description 18
- 235000007858 Hedysarum occidentale Nutrition 0.000 claims description 18
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 claims description 18
- 241000510654 Bupleurum chinense Species 0.000 claims description 16
- 241000007126 Codonopsis pilosula Species 0.000 claims description 16
- 240000004534 Scutellaria baicalensis Species 0.000 claims description 16
- 235000017089 Scutellaria baicalensis Nutrition 0.000 claims description 16
- 238000005303 weighing Methods 0.000 claims description 16
- 239000005711 Benzoic acid Substances 0.000 claims description 15
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 claims description 15
- 235000010233 benzoic acid Nutrition 0.000 claims description 15
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 claims description 15
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 15
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 claims description 14
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 claims description 14
- 230000007812 deficiency Effects 0.000 claims description 9
- 206010012735 Diarrhoea Diseases 0.000 claims description 6
- 208000031361 Hiccup Diseases 0.000 claims description 6
- 208000019790 abdominal distention Diseases 0.000 claims description 6
- 230000001154 acute effect Effects 0.000 claims description 6
- 208000022531 anorexia Diseases 0.000 claims description 6
- 206010061428 decreased appetite Diseases 0.000 claims description 6
- 206010003591 Ataxia Diseases 0.000 claims description 5
- 206010010947 Coordination abnormal Diseases 0.000 claims description 5
- 206010067715 Gastrointestinal sounds abnormal Diseases 0.000 claims description 5
- 239000002552 dosage form Substances 0.000 claims description 5
- 208000016290 incoordination Diseases 0.000 claims description 5
- 241000202726 Bupleurum Species 0.000 claims description 4
- 241000756943 Codonopsis Species 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 4
- 241000207929 Scutellaria Species 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 235000013399 edible fruits Nutrition 0.000 claims description 3
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract description 23
- 229940079593 drug Drugs 0.000 abstract description 10
- 230000001737 promoting effect Effects 0.000 abstract description 9
- 244000236521 Bupleurum rotundifolium Species 0.000 abstract description 7
- 235000015221 Bupleurum rotundifolium Nutrition 0.000 abstract description 7
- 238000005728 strengthening Methods 0.000 abstract description 6
- 230000003213 activating effect Effects 0.000 abstract description 5
- 210000004369 blood Anatomy 0.000 abstract description 5
- 239000008280 blood Substances 0.000 abstract description 5
- 241000721047 Danaus plexippus Species 0.000 abstract description 2
- 210000001124 body fluid Anatomy 0.000 abstract description 2
- 239000010839 body fluid Substances 0.000 abstract description 2
- 230000001914 calming effect Effects 0.000 abstract description 2
- 230000001939 inductive effect Effects 0.000 abstract description 2
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 229940126680 traditional chinese medicines Drugs 0.000 abstract description 2
- 230000001131 transforming effect Effects 0.000 abstract description 2
- 241000213006 Angelica dahurica Species 0.000 abstract 1
- 241000050051 Chelone glabra Species 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 47
- 241000700159 Rattus Species 0.000 description 46
- 239000007788 liquid Substances 0.000 description 26
- 241000234314 Zingiber Species 0.000 description 19
- 235000019441 ethanol Nutrition 0.000 description 15
- 210000002966 serum Anatomy 0.000 description 14
- 210000005229 liver cell Anatomy 0.000 description 13
- 230000001954 sterilising effect Effects 0.000 description 13
- 244000135727 Abrus pulchellus subsp cantoniensis Species 0.000 description 12
- 235000017112 Abrus pulchellus subsp cantoniensis Nutrition 0.000 description 12
- 210000005228 liver tissue Anatomy 0.000 description 12
- 208000022309 Alcoholic Liver disease Diseases 0.000 description 11
- 230000003908 liver function Effects 0.000 description 11
- 230000002829 reductive effect Effects 0.000 description 11
- 238000003745 diagnosis Methods 0.000 description 10
- 230000002496 gastric effect Effects 0.000 description 9
- 230000001965 increasing effect Effects 0.000 description 9
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 8
- 108010082126 Alanine transaminase Proteins 0.000 description 8
- 102100024889 Cytochrome P450 2E1 Human genes 0.000 description 8
- 102000004889 Interleukin-6 Human genes 0.000 description 8
- 108090001005 Interleukin-6 Proteins 0.000 description 8
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 8
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 8
- 229940100601 interleukin-6 Drugs 0.000 description 8
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 8
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 7
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 7
- 108010001202 Cytochrome P-450 CYP2E1 Proteins 0.000 description 7
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 102000019197 Superoxide Dismutase Human genes 0.000 description 7
- 108010012715 Superoxide dismutase Proteins 0.000 description 7
- 210000000038 chest Anatomy 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 229940118019 malondialdehyde Drugs 0.000 description 7
- 230000004060 metabolic process Effects 0.000 description 7
- 231100000240 steatosis hepatitis Toxicity 0.000 description 7
- 206010063659 Aversion Diseases 0.000 description 6
- 108020004206 Gamma-glutamyltransferase Proteins 0.000 description 6
- 206010019233 Headaches Diseases 0.000 description 6
- 206010037660 Pyrexia Diseases 0.000 description 6
- 208000019425 cirrhosis of liver Diseases 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 102000006640 gamma-Glutamyltransferase Human genes 0.000 description 6
- 231100000869 headache Toxicity 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 235000019658 bitter taste Nutrition 0.000 description 5
- 208000002173 dizziness Diseases 0.000 description 5
- 208000002672 hepatitis B Diseases 0.000 description 5
- 210000004969 inflammatory cell Anatomy 0.000 description 5
- 230000007863 steatosis Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- RYKKQQUKJJGFMN-HVDRVSQOSA-N 4,5-bis(hydroxymethyl)-2-methylpyridin-3-ol;(2s)-5-oxopyrrolidine-2-carboxylic acid Chemical compound OC(=O)[C@@H]1CCC(=O)N1.CC1=NC=C(CO)C(CO)=C1O RYKKQQUKJJGFMN-HVDRVSQOSA-N 0.000 description 4
- 206010002091 Anaesthesia Diseases 0.000 description 4
- 206010008479 Chest Pain Diseases 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 230000037005 anaesthesia Effects 0.000 description 4
- 230000000857 drug effect Effects 0.000 description 4
- 230000002440 hepatic effect Effects 0.000 description 4
- 206010029410 night sweats Diseases 0.000 description 4
- 230000036565 night sweats Effects 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 3
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 3
- 206010010904 Convulsion Diseases 0.000 description 3
- 108010052832 Cytochromes Proteins 0.000 description 3
- 102000018832 Cytochromes Human genes 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 208000006083 Hypokinesia Diseases 0.000 description 3
- 206010041349 Somnolence Diseases 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 238000001949 anaesthesia Methods 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000036461 convulsion Effects 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 206010013781 dry mouth Diseases 0.000 description 3
- 238000004043 dyeing Methods 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 210000003414 extremity Anatomy 0.000 description 3
- 208000010706 fatty liver disease Diseases 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 3
- 235000008216 herbs Nutrition 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000008595 infiltration Effects 0.000 description 3
- 238000001764 infiltration Methods 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 201000007270 liver cancer Diseases 0.000 description 3
- 208000014018 liver neoplasm Diseases 0.000 description 3
- 230000027939 micturition Effects 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- QLPRYZXNWYTFCI-UHFFFAOYSA-N saikosaponin D Natural products CC1OC(OC2CCC3(C)C(CCC4(C)C3C=CC56OCC7(CCC(C)(C)CC57)C(O)CC46C)C2(C)CO)C(O)C(O)C1OC8OC(CO)C(O)C(O)C8O QLPRYZXNWYTFCI-UHFFFAOYSA-N 0.000 description 3
- PQPVAGWUNWFCJE-UHFFFAOYSA-N saikosaponin a Natural products CC1OC(OC2CCC3(C)C(C2)C(C)(CO)CC4(C)C3C=CC56OCC7(CCC(C)(C)CC57)C(O)CC46C)C(O)C(OC8OC(CO)C(O)C(O)C8O)C1O PQPVAGWUNWFCJE-UHFFFAOYSA-N 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- 206010006784 Burning sensation Diseases 0.000 description 2
- 206010008469 Chest discomfort Diseases 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 206010015137 Eructation Diseases 0.000 description 2
- 208000004930 Fatty Liver Diseases 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 206010019708 Hepatic steatosis Diseases 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 206010028851 Necrosis Diseases 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 206010036790 Productive cough Diseases 0.000 description 2
- KYWSCMDFVARMPN-LCSVLAELSA-N Saikosaponin D Chemical compound O([C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@]([C@H]3[C@]([C@@H]4[C@@]([C@@]5(C[C@@H](O)[C@]67CO[C@]5([C@@H]6CC(C)(C)CC7)C=C4)C)(C)CC3)(C)CC2)(C)CO)O[C@@H]([C@@H]1O)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O KYWSCMDFVARMPN-LCSVLAELSA-N 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 208000026594 alcoholic fatty liver disease Diseases 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 206010016766 flatulence Diseases 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 210000000232 gallbladder Anatomy 0.000 description 2
- NLDDIKRKFXEWBK-AWEZNQCLSA-N gingerol Chemical class CCCCC[C@H](O)CC(=O)CCC1=CC=C(O)C(OC)=C1 NLDDIKRKFXEWBK-AWEZNQCLSA-N 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 230000002633 protecting effect Effects 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 208000037816 tissue injury Diseases 0.000 description 2
- 229910021642 ultra pure water Inorganic materials 0.000 description 2
- 239000012498 ultrapure water Substances 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 239000008096 xylene Substances 0.000 description 2
- OQWKEEOHDMUXEO-UHFFFAOYSA-N (6)-shogaol Natural products CCCCCC=CC(=O)CCC1=CC=C(O)C(OC)=C1 OQWKEEOHDMUXEO-UHFFFAOYSA-N 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 description 1
- KJPRLNWUNMBNBZ-QPJJXVBHSA-N (E)-cinnamaldehyde Chemical compound O=C\C=C\C1=CC=CC=C1 KJPRLNWUNMBNBZ-QPJJXVBHSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 208000007082 Alcoholic Fatty Liver Diseases 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 101000950981 Bacillus subtilis (strain 168) Catabolic NAD-specific glutamate dehydrogenase RocG Proteins 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 206010016262 Fatty liver alcoholic Diseases 0.000 description 1
- 102000016901 Glutamate dehydrogenase Human genes 0.000 description 1
- 208000000857 Hepatic Insufficiency Diseases 0.000 description 1
- 208000027761 Hepatic autoimmune disease Diseases 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 206010019668 Hepatic fibrosis Diseases 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 206010019728 Hepatitis alcoholic Diseases 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 101000909131 Homo sapiens Cytochrome P450 2E1 Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000483399 Ipimorpha retusa Species 0.000 description 1
- 241000827125 Lupinus flavoculatus Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- IPQKDIRUZHOIOM-UHFFFAOYSA-N Oroxin A Natural products OC1C(O)C(O)C(CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IPQKDIRUZHOIOM-UHFFFAOYSA-N 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 206010062519 Poor quality sleep Diseases 0.000 description 1
- 102000007584 Prealbumin Human genes 0.000 description 1
- 108010071690 Prealbumin Proteins 0.000 description 1
- KYWSCMDFVARMPN-MSSMMRRTSA-N Saikosaponin A Chemical group O([C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@]([C@H]3[C@]([C@@H]4[C@@]([C@@]5(C[C@H](O)[C@]67CO[C@]5([C@@H]6CC(C)(C)CC7)C=C4)C)(C)CC3)(C)CC2)(C)CO)O[C@@H]([C@@H]1O)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O KYWSCMDFVARMPN-MSSMMRRTSA-N 0.000 description 1
- 208000032140 Sleepiness Diseases 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- OQWKEEOHDMUXEO-BQYQJAHWSA-N [6]-Shogaol Chemical compound CCCCC\C=C\C(=O)CCC1=CC=C(O)C(OC)=C1 OQWKEEOHDMUXEO-BQYQJAHWSA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 208000002353 alcoholic hepatitis Diseases 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 210000000702 aorta abdominal Anatomy 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- IKIIZLYTISPENI-ZFORQUDYSA-N baicalin Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IKIIZLYTISPENI-ZFORQUDYSA-N 0.000 description 1
- 229960003321 baicalin Drugs 0.000 description 1
- AQHDANHUMGXSJZ-UHFFFAOYSA-N baicalin Natural products OC1C(O)C(C(O)CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 AQHDANHUMGXSJZ-UHFFFAOYSA-N 0.000 description 1
- 208000027687 belching Diseases 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229940117916 cinnamic aldehyde Drugs 0.000 description 1
- KJPRLNWUNMBNBZ-UHFFFAOYSA-N cinnamic aldehyde Natural products O=CC=CC1=CC=CC=C1 KJPRLNWUNMBNBZ-UHFFFAOYSA-N 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 230000002497 edematous effect Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000005485 electric heating Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000004149 ethanol metabolism Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 description 1
- 229940114124 ferulic acid Drugs 0.000 description 1
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 description 1
- 235000001785 ferulic acid Nutrition 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- JZLXEKNVCWMYHI-UHFFFAOYSA-N gingerol Natural products CCCCC(O)CC(=O)CCC1=CC=C(O)C(OC)=C1 JZLXEKNVCWMYHI-UHFFFAOYSA-N 0.000 description 1
- 235000002780 gingerol Nutrition 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000006372 lipid accumulation Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 208000015001 muscle soreness Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 1
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 description 1
- GYCKQBWUSACYIF-UHFFFAOYSA-N o-hydroxybenzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1O GYCKQBWUSACYIF-UHFFFAOYSA-N 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000007119 pathological manifestation Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 239000012192 staining solution Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 210000001562 sternum Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 230000003867 tiredness Effects 0.000 description 1
- 208000016255 tiredness Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 210000000626 ureter Anatomy 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/233—Bupleurum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/618—Molluscs, e.g. fresh-water molluscs, oysters, clams, squids, octopus, cuttlefish, snails or slugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/236—Ligusticum (licorice-root)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/282—Artemisia, e.g. wormwood or sagebrush
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/344—Codonopsis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/539—Scutellaria (skullcap)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/79—Schisandraceae (Schisandra family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/884—Alismataceae (Water-plantain family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9068—Zingiber, e.g. garden ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Nutrition Science (AREA)
- Otolaryngology (AREA)
- Hospice & Palliative Care (AREA)
- Marine Sciences & Fisheries (AREA)
- Zoology (AREA)
- Neurosurgery (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The application relates to the technical field of traditional Chinese medicines, in particular to a traditional Chinese medicine composition for preventing and treating alcoholic liver injury, and a preparation method and application thereof. Sixteen medicinal materials are taken as the whole prescription. The Chinese thorowax and cassia twig are used as monarch, the Chinese thorowax is used for soothing liver and gall Qi machine, the cassia twig Wen Tonggan is used for removing cold and harmonizing stomach, the dried ministerial drug Jiang Wenzhong is used for dispelling cold and harmonizing stomach, the szechuan lovage rhizome and the Chinese angelica are used for promoting qi circulation and tonifying blood, the dangshen, the poria cocos, the white atractylodes rhizome stir-fried with bran and the oriental waterplantain rhizome are used for strengthening spleen and promoting qi circulation and transforming middle-jiao Qi machine, the baical skullcap root is used for soothing liver and gall, the shaoyang is used for harmonizing liver and tonifying yang, the oyster is used for calming liver and suppressing yang, the Chinese thorowax is used for inducing the liver, the kudzuvine flower is used for activating spleen and dispelling alcohol, the abrus herb and the virgate wormwood herb are used for clearing and dispelling dampness and heat of liver, the schisandra chinensis is used for astringing yin and promoting the production of body fluid, the roasted liquorice is prepared by mixing medicines with the Chinese thorowax and cassia twig dried ginger Shang Hua.
Description
Technical Field
The invention relates to the technical field of traditional Chinese medicines, in particular to a traditional Chinese medicine composition for preventing and treating alcoholic liver injury, and a preparation method and application thereof.
Background
Alcoholic Liver Disease (ALD) is one of the most common types of liver disease worldwide, due to long-term or short-term consumption of alcohol, and has the pathological features of long duration and repeated persistence. ALD initially develops Alcoholic Fatty Liver (AFLD) and develops alcoholic hepatitis, liver fibrosis and cirrhosis, and severe cases can induce liver cancer or lead to liver failure, which is one of the leading causes of death. 90% of ethanol taken by human body is metabolized in liver, and poor ethanol metabolism is a main cause of alcoholic liver disease. At present, a plurality of health care products for dispelling the effects of alcohol and protecting the liver are on the market, but no medicament with definite curative effect is provided clinically.
The traditional Chinese medicine has relevant records such as 'wine hurting', 'wine stuffiness', and the like, and the traditional Chinese medicine considers that excessive drinking can lead damp evil to block liver and spleen, liver to lose and dredge, spleen failing to transport and lead to distending pain in chest and hypochondrium, anorexia, abdominal distention, hiccup, belch, borborygmus and gas in the vector, loose stool, takes soothing liver and harmonizing stomach, strengthening spleen and removing dampness as treatment rules, and simultaneously treats the response, causes and is suitable for people, and combines regional environmental climate characteristics and traditional Chinese medicine physique of people, thereby pertinently increasing the medicine taste dosage of main pathogenesis, and embodying the characteristic of dialectical treatment of traditional Chinese medicine.
The traditional Chinese medicine preparation for preventing and treating the alcoholic liver disease disclosed at present is not applied to the clinical animal and cell experimental results only in vivo and in vitro, has possibility of playing the drug effect in the animal experiment, but is ineffective for clinical use; the drug effect detection index of alcoholic liver injury of part of the traditional Chinese medicine preparation does not detect key cytokines, and the drug effect is possibly not obvious.
For example, a traditional Chinese medicine composition CN 116549576A for preventing and treating alcoholic liver injury has only pharmacodynamic experimental results of cells and mice in vitro and in vivo, is not supported by empirical data, and cannot support clinical curative effects.
For example, an anti-acute liver alcoholic liver injury traditional Chinese medicine composition, a preparation method and medical application CN 116585427A thereof disclose in vivo pharmacodynamic experiments, but lack of cytokine detection of CYP2E1, and cytochrome P4502E1 (cytochrome P4502E1, CYP2E 1) is a compound mainly located in liver cells and a metabolic enzyme of poison, is an important member of CYP450 metabolic enzyme family, plays an important role in metabolism and activation of toxic substrates such as alcohol, carbon tetrachloride and the like, cannot be explained by the patent application, and the effect of the cytokine cannot be possibly not obvious.
Therefore, the traditional Chinese medicine preparation which is extremely suitable for the physique of the patient with the alcoholic liver injury in the local area and can be accepted by clinic is found, is a regional civil health requirement, and has extremely remarkable practical significance.
Disclosure of Invention
In order to solve the technical problems in the prior art, the invention provides a traditional Chinese medicine composition for preventing and treating alcoholic liver injury, and a preparation method and application thereof. The method is realized by the following technical scheme:
a traditional Chinese medicine composition for preventing and treating alcoholic liver injury is characterized by comprising the following raw material components: radix bupleuri, radix Scutellariae, ramulus Cinnamomi, rhizoma Zingiberis, flos Puerariae Lobatae, concha Ostreae, rhizoma Chuanxiong, radix Angelicae sinensis, poria, rhizoma Atractylodis Macrocephalae preparata, rhizoma Alismatis, radix Codonopsis, fructus Schisandrae chinensis, herba abri, herba Artemisiae Scopariae, and radix Glycyrrhizae Preparata.
Further, the weight ratio of the raw materials is as follows: 1-5 parts of radix bupleuri, 1-5 parts of radix scutellariae, 1-5 parts of cassia twig, 1-3 parts of dried ginger, 1-5 parts of flos puerariae lobatae, 1-4 parts of oyster, 1-4 parts of ligusticum wallichii, 1-4 parts of angelica sinensis, 3-7 parts of poria cocos, 2-6 parts of bran-fried bighead atractylodes rhizome, 1-5 parts of rhizoma alismatis, 2-6 parts of radix codonopsis, 1-5 parts of schisandra chinensis, 2-6 parts of herba abri, 2-6 parts of herba artemisiae capillaris and 1-3 parts of honey-fried licorice root. Preferably, the weight ratio of the raw materials is as follows: 3 parts of bupleurum chinense, 3 parts of baical skullcap root, 3 parts of cassia twig, 1.6 parts of dried ginger, 3 parts of kudzuvine flower, 1.8 parts of oyster, 2 parts of szechuan lovage rhizome, 1.6 parts of Chinese angelica, 4.8 parts of Indian buead, 3.6 parts of white atractylodes rhizome fried with bran, 3 parts of oriental waterplantain rhizome, 4 parts of pilose asiabell root, 3 parts of Chinese magnoliavine fruit, 4 parts of abrus herb, 4 parts of virgate wormwood herb and 1.2 parts of prepared liquorice.
Further, auxiliary materials can be optionally added.
The preparation method of the traditional Chinese medicine composition for preventing and treating alcoholic liver injury comprises the following steps:
(1) Weighing the raw materials of bupleurum, scutellaria baicalensis, cassia twig, dried ginger, flos puerariae lobatae, oyster, ligusticum wallichii, angelica sinensis, poria cocos, bran-fried bighead atractylodes rhizome, rhizoma alismatis, codonopsis pilosula, schisandra chinensis, abrus herb, herba artemisiae capillaris, honey-fried licorice root and the like according to the proportion;
(2) Mixing the weighed Chinese medicinal materials, adding 8-12 times of water, decocting for 1-3 times, each for 1.5-2.5 hr, mixing decoctions, concentrating, standing, centrifuging, and collecting supernatant.
Further, pharmaceutically acceptable carriers and/or excipients can be added into the supernatant to prepare any clinically acceptable dosage form, and the finally obtained dosage form comprises tablets, pills, capsules, granules and medicinal granules. Further, specifically, a proper amount of steviosin, benzoic acid and ethyl hydroxybenzoate are added into the supernatant to prepare the mixture.
The application of the traditional Chinese medicine composition for preventing and treating alcoholic liver injury in the aspect of serving as/preparing acute alcoholic liver injury medicines.
The traditional Chinese medicine composition for preventing and treating alcoholic liver injury is applied to the preparation of medicines for treating chest and hypochondrium distending pain, anorexia, abdominal distention, hiccup, eructation, borborygmus, flatulence, loose stool and other diseases caused by incoordination between liver and stomach and spleen deficiency and dampness.
The traditional Chinese medicine composition disclosed by the application is consistent with the treatment rules of most of ' hurting wine ' and ' fullness in the wine ' by combining the physical characteristics of traditional Chinese medicine of patients in the local area, but has the regional characteristics, and secondly, the traditional Chinese medicine composition uses the road-area medicinal materials ' Gui Shiwei ' -Jigucao ' in the local area, and has a positive pushing effect on the development of national medical and health caregivers in the local area. Finally, the most important point of the composition is that the composition is higher than other similar compositions in clinic, the traditional Chinese medicine composition is clinically used for more than ten years, the composition is fully approved by clinic and patients, further the composition is processed and refined according to the characteristics of the combined medicine flavor, and finally the composition is prepared into a proper dosage form, so that the medicine effect is fully exerted.
Compared with the prior art, the invention has the technical effects that:
The pharmaceutical composition is a pure traditional Chinese medicine preparation, and has the effects of soothing liver, harmonizing stomach, dispelling the effects of alcohol and activating spleen. Can be used for treating chest and hypochondrium distending pain, anorexia, abdominal distention, singultus, belch, borygmus, flatulence, loose stool, etc. due to incoordination between liver and stomach and spleen deficiency and dampness. Sixteen medicinal materials are taken as the whole formula. The Chinese thorowax and cassia twig are used as monarch, the Chinese thorowax is used for soothing liver and gall Qi machine, the cassia twig Wen Tonggan is used for removing cold and harmonizing stomach, the dried ministerial drug Jiang Wenzhong is used for dispelling cold and harmonizing stomach, the szechuan lovage rhizome and the Chinese angelica are used for promoting qi circulation and tonifying blood, the dangshen, the poria cocos, the white atractylodes rhizome stir-fried with bran and the oriental waterplantain rhizome are used for strengthening spleen and promoting qi circulation and transforming middle-jiao Qi machine, the baical skullcap root is used for soothing liver and gall, the shaoyang is used for calming liver and suppressing yang, the oyster is used for inducing the liver, the kudzuvine flower is used for activating spleen and dispelling alcohol, the abrus herb and the virgate wormwood herb are used for clearing and dispelling dampness and heat of the liver, the Chinese magnoliavine fruit is used for astringing yin and promoting the production of body fluid, the roasted liquorice is used for harmonizing medicines, and the prescription is cut by the dried ginger Shang Hua of the Chinese thorowax twig, and the functions of soothing liver and harmonizing stomach, invigorating spleen and promoting diuresis and tonifying qi and nourishing blood are combined. Modern pharmacological researches show that bupleurum contains mainly saponin components, and the highest content is saikosaponin a and saikosaponin d. Wherein the saikosaponin d has different degrees of prevention and treatment effects on alcoholic liver disease, nonalcoholic steatohepatitis, liver cirrhosis, liver fibrosis and the like. The main ingredient of cassia twig is cinnamaldehyde, and the compatibility of the cassia twig and bupleurum is favorable for the dissolution of the purple Hu Zaogan, and the drug effect is enhanced. The dried ginger is rich in gingerol compounds, and researches show that gingerol and 6-shogaol can effectively improve liver lipid deposition. Both Ligusticum wallichii and Chinese angelica contain ferulic acid, and have good effects of resisting oxidization and inhibiting liver injury. The dangshen contains dangshen acetylenic glycoside, and has the pharmacological effects of treating gastric ulcer, promoting intestinal canal promotion, improving the digestion capacity of organisms and the like. The baicalin-containing radix Scutellariae has antioxidant and liver protecting effects. The components in the prescription act together, the modern pharmacological research action accords with the function and main treatment of soothing liver and harmonizing stomach oral liquid, all the medicinal herbs complement each other, the medicine of the prescription is combined with the pathogenesis of alcoholic fatty liver disease without going through, the physical characteristics of the traditional Chinese medicine in the local area are combined, the effect of relieving damp-heat toxin of viscera to dredge liver qi is emphasized, and the efficacy of soothing liver and activating spleen to relieve alcohol is achieved. The pharmaceutical composition is a compound preparation, has the effects of soothing liver and harmonizing stomach, dispelling the effects of alcohol and activating spleen in clinic for many years, can be used for treating chest and hypochondrium distending pain, anorexia, abdominal distention or hiccup, belch, borborygmus, loose stool and other diseases caused by incoordination between liver and stomach and spleen deficiency and dampness, and has obvious curative effect, small side effect and wide application.
Drawings
FIG. 1 is a flow chart of a preparation method.
FIG. 2 is a graph showing changes in liver histopathological morphology of rats (HE staining, 100×, 200×).
FIG. 3 is a graph showing the effect of liver soothing and gastric oral fluid on liver function index in rats with alcoholic liver injury model (A, B); results of the effect of liver soothing and gastric oral fluid on the oxidative balance in rats model of alcoholic liver injury (C, D).
FIG. 4 is a graph showing the effect of liver-soothing and stomach-harmonizing oral liquid on fat metabolism in rats with alcoholic liver injury model (A, B); the effect of liver soothing and stomach harmonizing oral liquid on serum inflammatory factors of rats with alcoholic liver injury model (C, D) is shown.
FIG. 5 is a graph showing the effect of liver soothing and stomach harmonizing oral liquid on serum and liver alcohol metabolism related enzymes of an alcoholic liver injury model rat.
Detailed Description
The technical scheme of the present invention is further defined below in conjunction with the specific embodiments, but the scope of the claimed invention is not limited to the description.
Example 1
(1) Weighing raw material Chinese medicinal materials such as 3g of bupleurum chinense, 3g of scutellaria baicalensis, 3g of cassia twig, 1.6g of dried ginger, 3g of flos puerariae lobatae, 1.8g of oyster, 2g of ligusticum wallichii, 1.6g of angelica sinensis, 4.8g of poria cocos, 3.6g of bighead atractylodes rhizome stir-fried with bran, 3g of rhizoma alismatis, 4g of codonopsis pilosula, 3g of schisandra chinensis, 4g of abrus cantoniensis hance, 4g of virgate wormwood herb, 1.2g of honey-fried licorice root and the like;
(2) Mixing the weighed Chinese medicinal materials, adding water 8 times of the weight of the Chinese medicinal decoction pieces, decocting for three times each for 1.5 hours, mixing decoctions, concentrating, standing, centrifuging, and collecting supernatant;
(3) Adding 20mg steviosin, 100mg benzoic acid and 20mg ethylparaben into the supernatant in step (2), sterilizing at 105deg.C for 40 min, and making into mixture.
Example 2
(1) Weighing 1g of bupleurum chinense, 5g of scutellaria baicalensis, 1g of cassia twig, 3g of dried ginger, 5g of flos puerariae lobatae, 4g of oyster, 4g of ligusticum wallichii, 4g of angelica sinensis, 7g of poria cocos, 6g of bighead atractylodes rhizome fried with bran, 5g of rhizoma alismatis, 6g of codonopsis pilosula, 5g of schisandra chinensis, 6g of abrus herb, 6g of virgate wormwood herb, 3g of honey-fried licorice root and other raw material Chinese medicinal herbs;
(2) Mixing the weighed Chinese medicinal materials, adding 8 times of water, decocting for three times each for 1.5 hours, mixing decoctions, concentrating, standing, centrifuging, and collecting supernatant;
(3) Adding 20mg steviosin, 100mg benzoic acid and 20mg ethylparaben into the supernatant in step (2), sterilizing at 105deg.C for 40 min, and making into mixture.
Example 3
(1) Weighing 5g of bupleurum chinense, 1g of scutellaria baicalensis, 5g of cassia twig, 1g of dried ginger, 1g of flos puerariae lobatae, 1g of oyster, 1g of ligusticum wallichii, 1g of angelica sinensis, 3g of poria cocos, 2g of bighead atractylodes rhizome fried with bran, 1g of rhizoma alismatis, 2g of codonopsis pilosula, 1g of schisandra chinensis, 2g of abrus herb, 2g of virgate wormwood herb, 1g of honey-fried licorice root and other raw material Chinese medicinal herbs;
(2) Mixing the weighed Chinese medicinal materials, adding 8 times of water, decocting for three times each for 1.5 hours, mixing decoctions, concentrating, standing, centrifuging, and collecting supernatant;
(3) Adding 20mg steviosin, 100mg benzoic acid and 20mg ethylparaben into the supernatant in step (2), sterilizing at 105deg.C for 40 min, and making into mixture.
Example 4
(1) Weighing raw material Chinese medicinal materials such as 3g of bupleurum chinense, 3g of scutellaria baicalensis, 3g of cassia twig, 1.6g of dried ginger, 3g of flos puerariae lobatae, 1.8g of oyster, 2g of ligusticum wallichii, 1.6g of angelica sinensis, 4.8g of poria cocos, 3.6g of bighead atractylodes rhizome stir-fried with bran, 3g of rhizoma alismatis, 4g of codonopsis pilosula, 3g of schisandra chinensis, 4g of abrus cantoniensis hance, 4g of virgate wormwood herb, 1.2g of honey-fried licorice root and the like;
(2) Mixing the weighed Chinese medicinal materials, adding 8 times of water, decocting for three times each for 1.5 hours, mixing decoctions, concentrating, standing, centrifuging, and collecting supernatant.
Example 5
(1) Weighing raw material Chinese medicinal materials such as 3g of bupleurum chinense, 3g of scutellaria baicalensis, 3g of cassia twig, 1.6g of dried ginger, 3g of flos puerariae lobatae, 1.8g of oyster, 2g of ligusticum wallichii, 1.6g of angelica sinensis, 4.8g of poria cocos, 3.6g of bighead atractylodes rhizome stir-fried with bran, 3g of rhizoma alismatis, 4g of codonopsis pilosula, 3g of schisandra chinensis, 4g of abrus cantoniensis hance, 4g of virgate wormwood herb, 1.2g of honey-fried licorice root and the like;
(2) Mixing the weighed Chinese medicinal materials, adding water 8 times of the weight of the Chinese medicinal decoction pieces, decocting for 1.5 hours each time, mixing decoctions, concentrating, standing, centrifuging, and collecting supernatant;
(3) Adding 20mg steviosin, 100mg benzoic acid and 20mg ethylparaben into the supernatant in step (2), sterilizing at 105deg.C for 40 min, and making into mixture.
Example 6
(1) Weighing raw material Chinese medicinal materials such as 3g of bupleurum chinense, 3g of scutellaria baicalensis, 3g of cassia twig, 1.6g of dried ginger, 3g of flos puerariae lobatae, 1.8g of oyster, 2g of ligusticum wallichii, 1.6g of angelica sinensis, 4.8g of poria cocos, 3.6g of bighead atractylodes rhizome stir-fried with bran, 3g of rhizoma alismatis, 4g of codonopsis pilosula, 3g of schisandra chinensis, 4g of abrus cantoniensis hance, 4g of virgate wormwood herb, 1.2g of honey-fried licorice root and the like;
(2) Mixing the weighed Chinese medicinal materials, adding water 10 times of the weight of the Chinese medicinal decoction pieces, decocting for 1.5 hr twice, mixing decoctions, concentrating, standing, centrifuging, and collecting supernatant;
(3) Adding 20mg steviosin, 100mg benzoic acid and 20mg ethylparaben into the supernatant in step (2), sterilizing at 105deg.C for 40 min, and making into mixture.
Example 7
(1) Weighing raw material Chinese medicinal materials such as 3g of bupleurum chinense, 3g of scutellaria baicalensis, 3g of cassia twig, 1.6g of dried ginger, 3g of flos puerariae lobatae, 1.8g of oyster, 2g of ligusticum wallichii, 1.6g of angelica sinensis, 4.8g of poria cocos, 3.6g of bighead atractylodes rhizome stir-fried with bran, 3g of rhizoma alismatis, 4g of codonopsis pilosula, 3g of schisandra chinensis, 4g of abrus cantoniensis hance, 4g of virgate wormwood herb, 1.2g of honey-fried licorice root and the like;
(2) Mixing the weighed Chinese medicinal materials, adding 12 times of water, decocting for three times each for 1.5 hr, mixing decoctions, concentrating, standing, centrifuging, and collecting supernatant;
(3) Adding 20mg steviosin, 100mg benzoic acid and 20mg ethylparaben into the supernatant in step (2), sterilizing at 105deg.C for 40 min, and making into mixture.
Example 8
(1) Weighing raw material Chinese medicinal materials such as 3g of bupleurum chinense, 3g of scutellaria baicalensis, 3g of cassia twig, 1.6g of dried ginger, 3g of flos puerariae lobatae, 1.8g of oyster, 2g of ligusticum wallichii, 1.6g of angelica sinensis, 4.8g of poria cocos, 3.6g of bighead atractylodes rhizome stir-fried with bran, 3g of rhizoma alismatis, 4g of codonopsis pilosula, 3g of schisandra chinensis, 4g of abrus cantoniensis hance, 4g of virgate wormwood herb, 1.2g of honey-fried licorice root and the like;
(2) Mixing the weighed Chinese medicinal materials, adding water 8 times of the weight of the Chinese medicinal decoction pieces, decocting for 2 hours each time, mixing decoctions, concentrating, standing, centrifuging, and collecting supernatant;
(3) Adding 20mg steviosin, 100mg benzoic acid and 20mg ethylparaben into the supernatant in step (2), sterilizing at 105deg.C for 40 min, and making into mixture.
Example 9
(1) Weighing raw material Chinese medicinal materials such as 3g of bupleurum chinense, 3g of scutellaria baicalensis, 3g of cassia twig, 1.6g of dried ginger, 3g of flos puerariae lobatae, 1.8g of oyster, 2g of ligusticum wallichii, 1.6g of angelica sinensis, 4.8g of poria cocos, 3.6g of bighead atractylodes rhizome stir-fried with bran, 3g of rhizoma alismatis, 4g of codonopsis pilosula, 3g of schisandra chinensis, 4g of abrus cantoniensis hance, 4g of virgate wormwood herb, 1.2g of honey-fried licorice root and the like;
(2) Mixing the weighed Chinese medicinal materials, adding water 10 times of the weight of the Chinese medicinal decoction pieces, decocting for three times each for 2 hours, mixing decoctions, concentrating, standing, centrifuging, and collecting supernatant;
(3) Adding 20mg steviosin, 100mg benzoic acid and 20mg ethylparaben into the supernatant in step (2), sterilizing at 105deg.C for 40 min, and making into mixture.
Example 10
(1) Weighing raw material Chinese medicinal materials such as 3g of bupleurum chinense, 3g of scutellaria baicalensis, 3g of cassia twig, 1.6g of dried ginger, 3g of flos puerariae lobatae, 1.8g of oyster, 2g of ligusticum wallichii, 1.6g of angelica sinensis, 4.8g of poria cocos, 3.6g of bighead atractylodes rhizome stir-fried with bran, 3g of rhizoma alismatis, 4g of codonopsis pilosula, 3g of schisandra chinensis, 4g of abrus cantoniensis hance, 4g of virgate wormwood herb, 1.2g of honey-fried licorice root and the like;
(2) Mixing the weighed Chinese medicinal materials, adding 12 times of water, decocting for 2 hr each time, mixing decoctions, concentrating, standing, centrifuging, and collecting supernatant;
(3) Adding 20mg steviosin, 100mg benzoic acid and 20mg ethylparaben into the supernatant in step (2), sterilizing at 105deg.C for 40 min, and making into mixture.
Example 11
(1) Weighing raw material Chinese medicinal materials such as 3g of bupleurum chinense, 3g of scutellaria baicalensis, 3g of cassia twig, 1.6g of dried ginger, 3g of flos puerariae lobatae, 1.8g of oyster, 2g of ligusticum wallichii, 1.6g of angelica sinensis, 4.8g of poria cocos, 3.6g of bighead atractylodes rhizome stir-fried with bran, 3g of rhizoma alismatis, 4g of codonopsis pilosula, 3g of schisandra chinensis, 4g of abrus cantoniensis hance, 4g of virgate wormwood herb, 1.2g of honey-fried licorice root and the like;
(2) Mixing the weighed Chinese medicinal materials, adding water 8 times of the weight of the Chinese medicinal decoction pieces, decocting for three times each for 2.5 hours, mixing decoctions, concentrating, standing, centrifuging, and collecting supernatant;
(3) Adding 20mg steviosin, 100mg benzoic acid and 20mg ethylparaben into the supernatant in step (2), sterilizing at 105deg.C for 40 min, and making into mixture.
Example 12
(1) Weighing raw material Chinese medicinal materials such as 3g of bupleurum chinense, 3g of scutellaria baicalensis, 3g of cassia twig, 1.6g of dried ginger, 3g of flos puerariae lobatae, 1.8g of oyster, 2g of ligusticum wallichii, 1.6g of angelica sinensis, 4.8g of poria cocos, 3.6g of bighead atractylodes rhizome stir-fried with bran, 3g of rhizoma alismatis, 4g of codonopsis pilosula, 3g of schisandra chinensis, 4g of abrus cantoniensis hance, 4g of virgate wormwood herb, 1.2g of honey-fried licorice root and the like;
(2) Mixing the weighed Chinese medicinal materials, adding water 10 times of the weight of the Chinese medicinal decoction pieces, decocting for 2.5 hours each time, mixing decoctions, concentrating, standing, centrifuging, and collecting supernatant;
(3) Adding 20mg steviosin, 100mg benzoic acid and 20mg ethylparaben into the supernatant in step (2), sterilizing at 105deg.C for 40 min, and making into mixture.
Example 13
(1) Weighing raw material Chinese medicinal materials such as 3g of bupleurum chinense, 3g of scutellaria baicalensis, 3g of cassia twig, 1.6g of dried ginger, 3g of flos puerariae lobatae, 1.8g of oyster, 2g of ligusticum wallichii, 1.6g of angelica sinensis, 4.8g of poria cocos, 3.6g of bighead atractylodes rhizome stir-fried with bran, 3g of rhizoma alismatis, 4g of codonopsis pilosula, 3g of schisandra chinensis, 4g of abrus cantoniensis hance, 4g of virgate wormwood herb, 1.2g of honey-fried licorice root and the like;
(2) Mixing the weighed Chinese medicinal materials, adding water 12 times of the weight of the Chinese medicinal decoction pieces, decocting for 2.5 hours each time, mixing decoctions, concentrating, standing, centrifuging, and collecting supernatant;
(3) Adding 20mg steviosin, 100mg benzoic acid and 20mg ethylparaben into the supernatant in step (2), sterilizing at 105deg.C for 40 min, and making into mixture.
Example 14
(1) Weighing raw material Chinese medicinal materials such as 3g of bupleurum chinense, 3g of scutellaria baicalensis, 3g of cassia twig, 1.6g of dried ginger, 3g of flos puerariae lobatae, 1.8g of oyster, 2g of ligusticum wallichii, 1.6g of angelica sinensis, 4.8g of poria cocos, 3.6g of bighead atractylodes rhizome stir-fried with bran, 3g of rhizoma alismatis, 4g of codonopsis pilosula, 3g of schisandra chinensis, 4g of abrus cantoniensis hance, 4g of virgate wormwood herb, 1.2g of honey-fried licorice root and the like;
(2) Mixing the weighed Chinese medicinal materials, adding water 12 times of the weight of the Chinese medicinal decoction pieces, decocting for 2.5 hours each time, mixing decoctions, concentrating, standing, centrifuging, and collecting supernatant;
(3) Adding 20mg steviosin, 100mg benzoic acid and 20mg ethylparaben into the supernatant in the step (2), sterilizing at 115 ℃ for 30 minutes, and preparing into a mixture.
Treatment effect test part:
1. The curative effect detection method comprises the following steps:
1. Determining a test object: the method comprises the steps of selecting 300 cases of patients with Western diagnosis meeting the diagnosis standard of alcoholic liver disease in the guide for preventing and treating alcoholic liver disease (updated version in 2018) and with Chinese medicine diagnosis meeting the diagnosis standard of liver depression and spleen deficiency in the guide for diagnosing and treating common diseases in Chinese medicine, grouping by adopting computer random codes, and hiding by adopting reasonable allocation, namely, loading the computer random codes into sealed envelopes to enable the patients to randomly extract, and sealing the codes by a designer. The 300 patients were randomly divided into 3 groups of 100 patients each;
wherein, the inclusion criteria are as follows:
Diagnostic criteria, traditional Chinese medicine diagnostics meet inclusion criteria:
① Age >18 years, unlimited for men and women;
② The history of drinking is more than or equal to 5 years, the amount of ethanol is more than or equal to 40g/d for men and 20g/d for women.
Exclusion criteria:
① Combining hepatophilic virus infection, drug and toxic liver disease, non-acute alcoholic liver injury, autoimmune liver disease, and genetic metabolism liver disease;
② Combining liver cancer or other malignant tumors;
③ Other severe primary diseases (cardiovascular and cerebrovascular diseases, kidney diseases, etc.);
④ Patients are reluctant to cooperate.
2. The usage amount is as follows: the mixture prepared in example 1 was orally taken. 20ml at a time, 2 times a day; or follow the doctor's advice. The composition is applied by shaking.
3. Standard of efficacy:
the clinical symptoms are completely eliminated, and main experimental indexes such as blood, liver functions and the like are restored to normal levels without diseases;
The clinical symptoms are obviously improved or the main symptoms disappear, and the laboratory indexes are recovered to be normal;
improvement, the main symptoms are controlled, partial symptoms possibly occur, but the disease is improved before the disease is developed;
Ineffective, symptoms fail to control or interrupt the treatment.
The total effective rate is the sum of clinical cure rate, obvious effect rate and good conversion rate.
4. The treatment effect is as follows: by using the mixture obtained in the example 1 of the invention for treatment for 1-2 months, in the case of the clinical observation patient, no side effects such as obvious abnormal reaction and the like are seen during the treatment period, and the specific curative effects are shown in the following table 1:
TABLE 1
Therefore, the invention has obvious effects for treating chest and hypochondrium distending pain, anorexia, abdominal distention, hiccup, belch, borborygmus, borygmus, loose stool and the like caused by incoordination between liver and stomach and spleen deficiency and dampness.
2. Introduction of specific cases:
1. the patient is in Tan certain, men, 34 years old
Complaints: the liver function was found to be abnormal for 5 days.
The current medical history: slight drowsiness and hypodynamia, no abdominal pain, no hypochondriac pain, no aversion to cold and fever, no cough and expectoration, no yellow urine of eyes, no dizziness and headache, occasionally dry mouth and bitter taste, no anaesthesia and greasiness, poor sleep and adjustment of urination. No significant decrease in body weight was seen after onset. The lower border of the liver is not touched under the hepatic rib, the liver-voiced sound border is normal, and the liver area is not tapped. The gallbladder is not reached, the gallbladder region is not painful, and the moat syndrome is negative. No mobility and no large spleen voice. The double kidney areas have no tap pain and the ureter has no pressure pain. Borborborygmus 5 times/min. Liver function: ALT159U/L, AST64U/L; two halves of hepatitis B: positive hepatitis B surface antibody, hepatitis B antibody and hepatitis B core antibody. Chest CT: no obvious abnormalities were seen in chest CT scans; fatty liver.
Western diagnosis: liver insufficiency; fatty liver
Diagnosis of traditional Chinese medicine: syndrome of liver depression and spleen deficiency
The treatment method comprises the following steps: liver soothing and spleen strengthening
The treatment method comprises the following steps: the oral liquid prepared in example 1 was orally administered. 20ml at a time, 2 times a day, 60 consecutive days.
Curative effect: the liver protection and the dialectical treatment of the traditional Chinese medicine are carried out in hospital, and the illness state of the patient is stable. Liver function, glutamic pyruvic transaminase (ALT) 87 ≡U/L. The patient has no abdominal pain, no hypochondriac pain, no aversion to cold and fever, no cough and expectoration, no yellow and dyed urine, no dizziness and headache, no greasy feeling, no somnolence and no adjustment of urination.
2. The patient is someplace on his or her trunk, male, 40 years old
Complaints: the whole body is tired and debilitated for more than 1 year, and the limb convulsion is carried out for 6 hours.
The current medical history: the whole body is drowsy and hypodynamia, no tiredness, dull pain in the right hypochondrium, bitter taste, no convulsion of limbs, muscle soreness of the two lower limbs, slight nausea, discomfort of gastric cavity, headache, no aversion to cold and fever, no damp heat and night sweat, no body yellow and dyeing of eyes. No significant weight loss was seen in recent times. Liver function: glutamic pyruvic transaminase 95 +.U/L and glutamic oxaloacetic transaminase 255 +.U/L.
Western diagnosis: liver cirrhosis decompensation period after hepatitis B
Diagnosis of traditional Chinese medicine: syndrome of liver depression and spleen deficiency
The treatment method comprises the following steps: liver soothing and spleen strengthening
The treatment method comprises the following steps: the oral liquid prepared in example 1 was orally administered. 20ml at a time, 2 times a day, 60 consecutive days.
Curative effect: the patients complain of general drowsiness and hypodynamia, no dull pain in the right hypochondrium, no bitter taste in the mouth, no convulsion in the limbs, no nausea, no headache and dizziness, no aversion to cold and fever, no damp heat and night sweat, no yellow eyes and normal urine and feces. Liver function VI, glutamic pyruvic transaminase (ALT) 51 ≡U/L, glutamic oxaloacetic transaminase (AST) 77 ≡U/L, gamma-glutamyl transferase (GGT) 405 ≡U/L and glutamate dehydrogenase 7.18 ≡U/L.
3. Patients with wei certain, men, 42 years old
Complaints: the distending pain of the epigastrium part is repeated for more than 3 months, and half a month is repeated.
The current medical history: the stomach pain, the pain of the stomach and the poststernum burning sensation, the pain of the right hypochondrium, the dry mouth and bitter taste, frequent belching, chest distress and discomfort, no aversion to cold and fever, no spontaneous perspiration and night sweat, headache and body pain, dizziness and waist soreness, chest distress and heart pain, no discomfort such as anaesthesia and greasiness, insomnia, convenient adjustment and no obvious decrease of the weight in recent years. The alcohol intake is about 80g every day for more than 10 years after long-term alcoholism, and the family history of liver cirrhosis and liver cancer is provided; overviews the history of infection such as viral hepatitis, tuberculosis and typhoid fever. Liver function: (national HR) glutamic pyruvic transaminase (ALT) 161.0 ≡U/L, (national HR) glutamic pyruvic transaminase (AST) 171.2 ≡U/L, (national HR) gamma-glutamyl transferase (GGT) 479 ≡U/L. Blood convention: WBCs, RBCs were slightly lowered. Upper abdominal color Doppler ultrasound: no abnormality.
Western diagnosis: alcoholic liver disease
Diagnosis of traditional Chinese medicine: syndrome of liver depression and spleen deficiency
The treatment method comprises the following steps: liver soothing and spleen strengthening
The treatment method comprises the following steps: the oral liquid prepared in example 1 was orally administered. 20ml at a time, 2 times a day, 60 consecutive days.
Curative effect: the patients have no obvious pain in the gastric cavity, no burning sensation after the gastric cavity and the sternum, sometimes pain in the right hypochondrium, no dry mouth and bitter taste, no belch, chest distress and discomfort, no aversion to cold and fever, no spontaneous perspiration and night sweat, no headache and body pain, no dizziness and waist soreness, no discomfort such as chest distress and heart pain, no anaesthesia and greasiness, and no insomnia and the like, and can regulate the urination and the defecation. Liver function vi: (national HR) glutamic pyruvic transaminase (ALT) 148.6 ≡U/L, (national HR) glutamic pyruvic transaminase (AST) 118.3 ≡U/L, (national HR) gamma-glutamyl transferase (GGT) 466 ≡U/L, prealbumin 382mg/L. Hepatitis B virus deoxyribonucleic acid assay <1.00E+02IU/mL.
3. Rat animal experiment:
the purpose is as follows: the liver protection effect of liver soothing and stomach harmonizing oral liquid on rats with acute alcoholic liver injury is explored.
The method comprises the following steps: SD rats are randomly divided into a normal group, a model group, a metadoxine (50 mg/kg) group, a low-dosage group and a high-dosage group (3, 6g/kg, which are equivalent to 3,6 times of the equivalent dosage of clinical adults) of liver soothing and stomach harmonizing oral liquid, gradient infusion is adopted to prepare acute alcoholic liver injury models of rats by taking distilled spirit with different concentrations, and corresponding medicines or distilled water are infused during the modeling for 14 days. HE staining observed liver tissue pathology and scored; the kit detects indexes such as rat serum glutamic pyruvic transaminase (ALT), glutamic oxaloacetic transaminase (AST), superoxide dismutase (SOD), malondialdehyde (MDA), triacylglycerol (TG), total Cholesterol (TC), tumor necrosis factor-alpha (TNF-alpha), interleukin 6 (IL-6) and the like and expression levels such as Alcohol Dehydrogenase (ADH), cytochrome P4502E1 (CYP 2E 1) and the like in the liver. Compared with the normal control group, the liver cells of the liver tissue of the rat in the model group have obvious pathological damage, the contents of serum ALT, AST, MDA, TC, TG, TNF-alpha, IL-6 and CYP2E1 are obviously increased (P is less than 0.01), the activity of SOD is obviously reduced (P is less than 0.01), and the expression of ADH in the liver tissue is obviously reduced (P is less than 0.01). Compared with the model group, the liver-soothing and stomach-harmonizing oral liquid has obviously reduced pathological injury of liver cells of rats in each dosage group, obviously reduced contents of serum ALT, AST, MDA, TC, TG, TNF-alpha, IL-6 and CYP2E1 (P < 0.05 or P < 0.01), and obviously increased activity of serum SOD and liver tissue ADH (P < 0.01).
Conclusion: the liver soothing and stomach harmonizing oral liquid can effectively relieve liver tissue injury of rats with alcoholic liver disease, and the mechanism of the liver soothing and stomach harmonizing oral liquid is possibly related to relieving oxidative stress of liver cells, lipid accumulation and inflammatory reaction.
The specific experimental contents are as follows:
1 Material
1.1 Test drug
The liver soothing and stomach harmonizing oral liquid is provided by a preparation room of a traditional Chinese medicine hospital in Liuzhou market (batch number 20231001, the specific ratio of the raw materials is the same as that of example 1); metadoxine capsule (specification: 0.25 g/granule, lot number 221001), purchased from Zhejiang Jiyuan pharmaceutical Co., ltd, and prepared with ultra-pure water; 43% strength white spirit (lot 2022123139) and 56% strength white spirit (lot 2022092037) were purchased from Beijing red star Co., ltd.
1.2 Animals
SPF-grade male SD rats were 25, mass (150.+ -.10) g, purchased from Guangdong Vetolihua laboratory animal technologies Co., ltd., laboratory animal mass eligibility number: 44829700021770, the feeding environment is as follows: placing in IVC rat cage, and circulating for 12 hr at relative temperature (25+ -2deg.C) and relative humidity (50+ -5%). 5 animals per cage, after 5 days of adaptive feeding, the formal test is started.
1.3 Reagents
ALT, AST, SOD, MDA, TC, TG, ADH detection kit (Nanjing institute of biological engineering, lot numbers 20231103, 20231103, 20231016, 20231101, 20231108, 20231108, 20231016, respectively); TNF-alpha, CYP2E1, IL-6 enzyme linked immunoassay kit (Wuhan Hua Likeside biotechnology Co., ltd., batch number 20231010); 4% paraformaldehyde (lot 21235935, siring biosciences, guangzhou); hematoxylin-eosin (HE) staining solution (beijing solibao technologies limited, lot 20210419).
1.4 Instruments
Bio-Rad iMark microplate reader (Shanghai Berle Life medicine Co., ltd.; model: bio-Rad 680); electric heating constant temperature water bath (Ningbo Xinzhi biotechnology Co., ltd., model: SC-20); a high-speed low-temperature centrifuge (model: TGD-20MC, manufactured by Changsha sharp centrifuge Co., ltd.); ice machine (model: IMS-130, established snow refrigeration equipment limited); ultrapure water machine (Beijing general analysis general instruments Co., ltd., model: GWB-1).
2 Method
2.1 Grouping, modeling, and administration methods for animals
25 SD rats were randomly divided into a normal group, a model group, metadoxine 50mg/kg group, a liver soothing and stomach harmonizing oral liquid soup low and high dose group (3, 6g/kg, equivalent to 3, 6 times of the clinical adult equivalent dose) of 5 each. An acute alcoholic liver injury animal model [1] is constructed by referring to the model preparation specifications proposed by the Chinese medical science of the Chinese traditional medicine laboratory pharmacology professional committee. 1 d-4 d, except that rats in the normal control group are subjected to gastric lavage with distilled water every day, rats in each group are subjected to gastric lavage with 10mL/kg of 43% concentration white spirit twice a day at intervals of 8 hours. And 5 d-14 d, filling the stomach of rats in each group with distilled water every day except for rats in the normal control group, wherein the rats in each group are filled with 10mL/kg of 56% concentration white spirit twice a day at intervals of 8 hours. After 1h of each alcohol infusion, each group of corresponding drugs or pure water was administrated by stomach infusion, and the administration volume was 10mL/kg for 14 days.
2.2 Sample collection
After the last administration, the rats of each group are fasted without water control for 12 hours, and the abdominal aorta after anesthesia is sampled and kept stand for 1 hour at room temperature. Centrifuging at 3500r/min for 10min, collecting supernatant, packaging, and transferring to-80deg.C refrigerator for storage. Two pieces of liver tissue with the same size are respectively taken at the same position of the left leaf and the right leaf of the liver of each rat. The left hepatic leaf tissue is frozen and stored in a refrigerator at the temperature of minus 80 ℃, and the right hepatic leaf tissue is fixed in 4% formaldehyde fixing solution and is used for HE staining to observe pathological changes of the hepatic tissue.
2.3 Liver histopathological examination
Taking out the fixed liver tissue sample, slicing, dehydrating with gradient ethanol, and making xylene transparent. After treatment, the sections are placed in hematoxylin dye solution, after 5min of dyeing, the sections are rinsed with tap water, differentiated and rinsed with differentiation solution, and rinsed with running water after returning to blue. Dewatering with 85% and 95% gradient alcohol for 5min, and adding eosin dye solution for dyeing for 5min. And (3) dehydrating by absolute ethyl alcohol, and sealing the neutral resin after the xylene is transparent. The liver histopathological changes of the rats in each group are observed under an electron microscope, and the inflammatory cell infiltration condition of liver tissues, the hepatic cell steatosis, the hepatic fibrosis and the like are examined. The literature uses a Knodell scoring system to evaluate [3] the pathological manifestations of liver tissue, a pathology negative score of 0, a weak positive score of 1, a positive score of 2, and a strong positive score of 3.
2.4 Biochemical index detection
Preparing relevant solutions and samples according to ALT, AST, SOD, MDA, TC, TG, TNF-alpha, IL-6 and CYP2E1 detection kit specifications, uniformly mixing all the reagents, detecting the index absorbance of the rat serum by using an enzyme-labeling instrument, drawing a standard curve according to the absorbance and the standard concentration, and calculating the index concentrations of the rat serum of each group according to the absorbance of the samples.
2.5 Statistical methods
Data processing and metering by SPSS20.0The comparison among multiple groups is firstly performed with variance alignment test, the variance alignment person selects ANOVA for single-factor variance analysis, LSD is used for pairwise comparison, and P is smaller than 0.05 to indicate that the difference has statistical significance.
3 Results
3.1 Effects of liver soothing and stomach harmonizing oral liquid on liver tissue pathological changes in rats with alcoholic liver injury model
The liver lobule structure of the normal group rat is clear and normal, the liver cells are orderly arranged radially from the central vein to the periphery, and the liver cells have no degeneration, necrosis and inflammatory cell infiltration; the liver lobule cells of the rats in the model group are arranged in disorder, the liver cells around the central vein are swollen, the liver cells have focal necrosis, inflammatory cells infiltrate, and the intracytoplasmic vesicular steatosis is seen; the liver lobule structure of metadoxine group rats is basically normal, and the liver cells rarely have edema and steatosis; the liver soothing and stomach harmonizing oral liquid has various improving effects, wherein liver lobules of rats in liver soothing and stomach harmonizing oral liquid-L groups are basically normal, liver cells are slightly edematous, a small amount of inflammatory cells infiltrate is visible, and liver cell steatosis is not visible; liver soothing and stomach harmonizing oral liquid-H group rat liver cells liver lobule structure is normal, and liver cell edema, steatosis and inflammatory cell infiltration are not seen. And the improvement effect of the liver-soothing and stomach-harmonizing oral liquid-H group is better than that of the metastatin group. See fig. 2.
3.2 Effects of liver soothing and stomach harmonizing oral liquid on liver function index of alcoholic liver injury model rats
Compared with the normal group, the serum ALT and AST activities of the rats in the model group are obviously improved (p < 0.01). Compared with the model group, the activity of ALT and AST in rat serum in liver-soothing and stomach-harmonizing oral liquid-L and liver-soothing and stomach-harmonizing oral liquid-H groups is obviously reduced (p is less than 0.01). See fig. 3A, B.3.3 effects of liver soothing and stomach harmonizing oral liquid on the oxidative balance in rats model of alcoholic liver injury
The model group rats had significantly reduced SOD activity (p < 0.01) and significantly increased MDA content (p < 0.01) compared to the normal group. Compared with the model group, the SOD content of each dosage group of the liver-soothing and stomach-harmonizing oral liquid is obviously increased (p < 0.01), and the activity of MDA is obviously reduced (p < 0.01). See fig. 3C, D.
3.4 Effects of liver soothing and gastric oral liquid on fat metabolism in alcoholic liver injury model rats compared with normal groups, the serum TG and TC contents of the model rats are obviously increased (p < 0.01); compared with the model group, the content of TG and TC in each dosage group of the liver-soothing and stomach-soothing oral liquid is obviously reduced (p < 0.01). See FIG. 3 (A, B).
3.5 The effects of liver soothing and gastric oral liquid on serum inflammatory factors of rats with alcoholic liver injury models are compared with normal groups, and the serum TNF-alpha and IL-6 contents of rats with the models are obviously increased (p < 0.01); compared with the model group, the content of TNF-alpha and IL-6 in each dosage group of the liver-soothing and stomach-soothing oral liquid is obviously reduced (p < 0.01). See FIG. 3 (C, D).
3.6 Effects of liver soothing and stomach harmonizing oral liquid on serum and liver alcohol metabolism related enzymes of rats with alcoholic liver injury model
Model group rats had significantly reduced ADH activity (p < 0.01) and significantly increased CYP2E1 content (p < 0.01) compared to the normal group. Compared with the model group, the ADH content of each dosage group of the liver-soothing and stomach-harmonizing oral liquid is obviously increased (p < 0.01), and the CYP2E1 activity is obviously reduced (p < 0.01). See fig. 4A, B.
In conclusion, the liver soothing and stomach harmonizing oral liquid is found to be capable of effectively relieving liver tissue injury of rats with alcoholic liver disease, improving liver function, restoring internal oxidation balance and promoting liver fat metabolism through detecting indexes of rat in whole state, liver tissue pathological morphology, biochemistry, molecular biology and the like, so that the protective effect of alcoholic liver injury is exerted
Finally, it should be noted that the above embodiments are merely representative examples of the present invention. Obviously, the technical solution of the invention is not limited to the above-described embodiments, but many variations are possible. All modifications directly derived or suggested to one skilled in the art from the present disclosure should be considered as being within the scope of the present invention.
Claims (10)
1. A traditional Chinese medicine composition for preventing and treating alcoholic liver injury is characterized by comprising the following raw material components: radix bupleuri, radix Scutellariae, ramulus Cinnamomi, rhizoma Zingiberis, flos Puerariae Lobatae, concha Ostreae, rhizoma Chuanxiong, radix Angelicae sinensis, poria, rhizoma Atractylodis Macrocephalae preparata, rhizoma Alismatis, radix Codonopsis, fructus Schisandrae chinensis, herba abri, herba Artemisiae Scopariae, and radix Glycyrrhizae Preparata.
2. The traditional Chinese medicine composition for preventing and treating alcoholic liver injury according to claim 1, wherein the weight ratio of the raw materials is as follows: 1-5 parts of radix bupleuri, 1-5 parts of radix scutellariae, 1-5 parts of cassia twig, 1-3 parts of dried ginger, 1-5 parts of flos puerariae lobatae, 1-4 parts of oyster, 1-4 parts of ligusticum wallichii, 1-4 parts of angelica sinensis, 3-7 parts of poria cocos, 2-6 parts of bran-fried bighead atractylodes rhizome, 1-5 parts of rhizoma alismatis, 2-6 parts of radix codonopsis, 1-5 parts of schisandra chinensis, 2-6 parts of herba abri, 2-6 parts of herba artemisiae capillaris and 1-3 parts of honey-fried licorice root.
3. The traditional Chinese medicine composition for preventing and treating alcoholic liver injury according to claim 2, wherein the weight ratio of the raw materials is as follows: 3 parts of bupleurum chinense, 3 parts of baical skullcap root, 3 parts of cassia twig, 1.6 parts of dried ginger, 3 parts of kudzuvine flower, 1.8 parts of oyster, 2 parts of szechuan lovage rhizome, 1.6 parts of Chinese angelica, 4.8 parts of Indian buead, 3.6 parts of white atractylodes rhizome fried with bran, 3 parts of oriental waterplantain rhizome, 4 parts of pilose asiabell root, 3 parts of Chinese magnoliavine fruit, 4 parts of abrus herb, 4 parts of virgate wormwood herb and 1.2 parts of prepared liquorice.
4. The traditional Chinese medicine composition for preventing and treating alcoholic liver injury according to claim 1, wherein auxiliary materials are also added.
5. The method for preparing the traditional Chinese medicine composition for preventing and treating alcoholic liver injury according to any one of claims 1 to 4, which is characterized by comprising the following steps:
(1) Weighing the raw materials of bupleurum, scutellaria baicalensis, cassia twig, dried ginger, flos puerariae lobatae, oyster, ligusticum wallichii, angelica sinensis, poria cocos, bran-fried bighead atractylodes rhizome, rhizoma alismatis, codonopsis pilosula, schisandra chinensis, abrus herb, herba artemisiae capillaris, honey-fried licorice root and the like according to the proportion;
(2) Mixing the weighed Chinese medicinal materials, adding 8-12 times of water, decocting for 1-3 times, each for 1.5-2.5 hr, mixing decoctions, concentrating, standing, centrifuging, and collecting supernatant.
6. The method for preparing the traditional Chinese medicine composition for preventing and treating alcoholic liver injury according to claim 5, wherein a pharmaceutically acceptable carrier and/or excipient can be added into the supernatant to prepare any clinically acceptable dosage form.
7. The method for preparing a traditional Chinese medicine composition for preventing and treating alcoholic liver injury according to claim 6, wherein the finally obtained dosage form comprises mixture, tablet, pill, capsule, granule and electuary.
8. The method for preparing a Chinese medicinal composition for preventing and treating alcoholic liver injury according to claim 6, wherein a proper amount of steviosin, benzoic acid and ethylparaben are added into the supernatant to prepare the mixture.
9. Use of the traditional Chinese medicine composition for preventing and treating alcoholic liver injury according to any one of claims 1-4 as/in preparing acute alcoholic liver injury medicine.
10. The use of the Chinese medicinal composition for preventing and treating alcoholic liver injury according to any one of claims 1-4 as/for preparing a medicament for treating chest and hypochondrium distending pain, anorexia, abdominal distention, hiccup, belch, borborygmus, and loose stool caused by incoordination between liver and stomach and spleen deficiency and dampness.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311710863.3A CN117919365A (en) | 2023-12-13 | 2023-12-13 | Traditional Chinese medicine composition for preventing and treating alcoholic liver injury as well as preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311710863.3A CN117919365A (en) | 2023-12-13 | 2023-12-13 | Traditional Chinese medicine composition for preventing and treating alcoholic liver injury as well as preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117919365A true CN117919365A (en) | 2024-04-26 |
Family
ID=90752629
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311710863.3A Pending CN117919365A (en) | 2023-12-13 | 2023-12-13 | Traditional Chinese medicine composition for preventing and treating alcoholic liver injury as well as preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117919365A (en) |
-
2023
- 2023-12-13 CN CN202311710863.3A patent/CN117919365A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MXPA03003446A (en) | Novel medicinal herbal composition for treating liver diseases and hiv. | |
| CN110787233B (en) | Liver-protecting traditional Chinese medicine composition, extract and pharmaceutical application thereof | |
| CN103301412A (en) | Traditional Chinese medicine composition for treating alcoholic liver | |
| CN104644915A (en) | Pharmaceutical composition for treating alcoholic liver diseases as well as preparation method and application of pharmaceutical composition | |
| CN102988675B (en) | Traditional Chinese medicine combination for treating chronic prostatitis and preparation method thereof | |
| CN103223069A (en) | Traditional Chinese medicine composition for treating hepatitis | |
| CN103301267A (en) | Traditional Chinese medicine composition for treating hypertension and/or atherosclerosis and application thereof | |
| CN103041262B (en) | Traditional Chinese medicine enema for curing chronic prostatitis and preparing method thereof | |
| CN105561006A (en) | Food, health care food or medicine composition with alcohol effect dispelling function and preparation method and application thereof | |
| CN100423754C (en) | Medicine for treating chronic alcoholic hepatopathy and its preparing method | |
| CN115487280B (en) | Traditional Chinese medicine composition for dispelling effects of alcohol, protecting liver and promoting liver regeneration as well as preparation and preparation method thereof | |
| CN103007145B (en) | Traditional Chinese medicine composition for treating children rotavirus enteritis and preparation method of composition | |
| CN117919365A (en) | Traditional Chinese medicine composition for preventing and treating alcoholic liver injury as well as preparation method and application thereof | |
| CN104042895A (en) | Traditional Chinese medicine composition for treating systemic lupus erythematosus and use thereof | |
| CN103830337B (en) | Chinese medicinal composition for treating chronic alcoholic toxic liver disease | |
| CN101874858B (en) | Traditional Chinese medicine for treating virus hepatitis and preparation method thereof | |
| CN112220846A (en) | Traditional Chinese medicine composition for treating children's chronic cough and application thereof | |
| CN103316106A (en) | Danshan fat reducing granules and preparation method thereof | |
| CN117982557B (en) | Use of fermented soya bean ginger or its extract and its composition | |
| CN116687994B (en) | Application of honeysuckle in preparation of medicine for reducing toxicity of radix aconiti | |
| CN111870628B (en) | Medicine for treating chronic hepatitis B | |
| CN102000303B (en) | Compound traditional Chinese medicine preparation for suppressing tumors | |
| CN105943860A (en) | Medicine preparation for treating diabetes mellitus and preparation method thereof | |
| CN106727958A (en) | It is a kind of to treat pharmaceutical composition of alcoholic hepatitis and preparation method thereof | |
| CN105535571A (en) | Detoxifying, dehumidifying, liver-protecting and cholagogic plantain seed oral liquid and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |